Hefei Lakebio Medical Technologies Co.,Ltd – Trademark Portfolio
Entity Type: 99
Hefei Lakebio Medical Technologies Co.,Ltd holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include LAKEBIO. The owner is based in Anhui,.
F Zone, 4th Floor, Building 3, Mingzhu
Industrial Park, High-tech Zone, Hefei,
Anhui, 230000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Hefei Lakebio Medical Technologies Co.,Ltd's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Hefei Lakebio Medical Technologies Co.,Ltd have?
Hefei Lakebio Medical Technologies Co.,Ltd has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 abandoned.
What trademark classes does Hefei Lakebio Medical Technologies Co.,Ltd file in?
Hefei Lakebio Medical Technologies Co.,Ltd files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Hefei Lakebio Medical Technologies Co.,Ltd's most well-known trademarks?
Hefei Lakebio Medical Technologies Co.,Ltd's registered trademark portfolio includes well-known marks such as LAKEBIO. These are among 2 currently registered trademarks in the portfolio.
What is Hefei Lakebio Medical Technologies Co.,Ltd's trademark registration success rate?
Hefei Lakebio Medical Technologies Co.,Ltd has a 50% trademark registration rate, with 2 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.